Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

Biotech leaders jump into US free speech debate

Senior biotech execs sign a letter in defence of free speech

- PMLiVE

Q&A: Jenny Squibbs The best and worst things about working in healthcare comms

Gemma Jones interviews 90TEN's senior account director

- PMLiVE

Viking throws down gauntlet in NASH battle

Biotech is challenging rival Madrigal in 'next big thing' disease area

- PMLiVE

London cancer hub launched by Cancer Research UK

Specialist centres unite to collaborate on immunotherapies such as CAR-T

- PMLiVE

Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma

Proactive adjuvant treatment could extend melanoma patient lives

- PMLiVE

Tox trouble stalls Sosei/Allergan Alzheimer’s drug

Surprise findings from primate studies

Making a Difference – The Future of Pharma

On a global scale, pharma is one of the least-trusted industries. And this is despite the fact that pharma contributes more than £30 BN each year to the UK economy,...

Lucid Group Communications Limited

- PMLiVE

Teva wins FDA OK for crucial migraine drug

Vital to Teva's turnaround, Ajovy will challenge Novartis/Amgen's Aimovig

- PMLiVE

AZ prepares to file COPD triple, taking on rival GSK

Latest salvo in combination trials competition

- PMLiVE

Controversy grows around GP at Hand service after minister’s endorsement

Hancock says service should be rolled out across England

- PMLiVE

AZ nabs US approval for new leukaemia drug Lumoxiti

Adds to firm's growing oncology franchise

- PMLiVE

New data keeps AbbVie’s star pipeline therapies on track

Data showed 56% of patients on risankizumab were symptom free after a year’s treatment

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links